Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

被引:130
作者
Sholl, Lynette M. [1 ]
Weremowicz, Stanislawa [1 ]
Gray, Stacy W. [2 ]
Wong, Kwok-Kin [2 ]
Chirieac, Lucian R. [1 ]
Lindeman, Neal I. [1 ]
Hornick, Jason L. [1 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Thorac Oncol, Boston, MA 02115 USA
关键词
Anaplastic lymphoma kinase; Lung adenocarcinoma; Fluorescence in situ hybridization; Immunohistochemistry; CANCER; FUSION; MUTATIONS; GEFITINIB; EGFR;
D O I
10.1097/JTO.0b013e31827db604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: ALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma kinase (ALK) overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the standard procedure for detection of ALK rearrangements in lung ACA but requires specialized equipment and expertise. Immunohistochemistry (IHC) for ALK protein overexpression is a promising screening modality, with reports of newer antibodies showing excellent sensitivity and specificity for ALK-rearranged lung ACA. Methods: In this study, we analyzed ALK IHC (5A4 clone) in 186 cases from our clinical service and compared it with ALK FISH and EGFR and KRAS mutation status. Results: Twelve cases had concordant ALK protein overexpression and ALK rearrangement by FISH. Three ALK-rearranged cases lacked ALK protein expression. Of these discrepant cases, one had a coexisting EGFR mutation and a subtle atypical ALK rearrangement manifested as a break in the 5' centromeric portion of the FISH probe. One case had a concurrent BRAF mutation. Follow-up testing on a metastasis revealed absence of the ALK rearrangement, with persistent BRAF mutation. In one ALK-rearranged protein negative case, very limited tissue remained for ALK IHC, raising the possibility of false negativity because of protein expression heterogeneity. Importantly, ALK protein expression was detected in one case initially thought not to have an ALK rearrangement. In this case, FISH was falsely negative because of interference by benign reactive nuclei. After correcting for these cases, ALK IHC was 93% sensitive and 100% specific as compared with FISH. Conclusions: ALK IHC improves the detection of ALK rearrangements when used together with FISH, and its use in lung ACA genetic testing algorithms should be considered.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [31] Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC)
    Shen, Qin
    Wang, Xuan
    Yu, Bo
    Shi, Shanshan
    Liu, Biao
    Wang, Yanfen
    Xia, Qiuyuan
    Rao, Qiu
    Zhou, Xiaojun
    LUNG CANCER, 2015, 90 (03) : 492 - 498
  • [32] ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India
    Bal, Amanjit
    Singh, Navneet
    Agarwal, Parimal
    Das, Ashim
    Behera, Digambar
    APMIS, 2016, 124 (10) : 832 - 838
  • [33] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
    Shiihara, Jun
    Ohyanagi, Fumiyoshi
    Amari, Hikari
    Toda, Minemichi
    Tahara, Hiroki
    Yuzawa, Motoi
    Maeda, Yuki
    Nomura, Motoko
    Mizushina, Yoshiko
    Nagai, Yoshiaki
    Ohta, Hiromitsu
    Yamaguchi, Yasuhiro
    THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
  • [34] A case of ALK-rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone
    Miyashita, Yoshihiro
    Hanawa, Kotaro
    Kobayashi, Hiroaki
    Kumagai, Takashi
    Inomata, Kie
    Tsutsui, Toshiharu
    Kakizaki, Yumiko
    Oyama, Toshio
    RESPIRATORY MEDICINE CASE REPORTS, 2020, 30
  • [35] Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
    Kanaan, Zeyad
    Kloecker, Goetz H.
    Paintal, Ajit
    Perez, Cesar A.
    ONCOTARGETS AND THERAPY, 2015, 8 : 885 - 892
  • [36] Targeting ALK-rearranged non-small-cell lung cancer: an update
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2017, 13 (14) : 1213 - 1217
  • [37] Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report
    Siblini, Laura
    Schott, Roland
    Trensz, Philippe
    Pencreach, Erwan
    Bender, Laura
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2342 - 2346
  • [38] Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
    Hout, David R.
    Schweitzer, Brock L.
    Lawrence, Kasey
    Morris, Stephan W.
    Tucker, Tracy
    Mazzola, Rosetta
    Skelton, Rachel
    McMahon, Frank
    Handshoe, John
    Lesperance, Mary
    Karsan, Aly
    Saltman, David L.
    CANCERS, 2017, 9 (08)
  • [39] The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma
    Feng, Tingting
    Chen, Zhongzhong
    Gu, Jianjun
    Wang, Yuxiu
    Zhang, Jun
    Min, Lingfeng
    LUNG CANCER, 2019, 137 : 19 - 22
  • [40] Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
    Leung, Jackson Ka Chun
    Kwok, Wang Chun
    Leung, Arthur Chun Fung
    Tsui, Po
    Ho, James Chung-Man
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (07):